Definium Therapeutics Target of Unusually Large Options Trading (NASDAQ:DFTX)

Definium Therapeutics, Inc. (NASDAQ:DFTX) was the recipient of unusually large options trading on Friday. Stock traders purchased 8,130 call options on the stock. This represents an increase of 460% compared to the typical volume of 1,451 call options.

Definium Therapeutics Price Performance

Shares of NASDAQ:DFTX traded up $0.64 during midday trading on Friday, reaching $24.75. The company’s stock had a trading volume of 1,727,239 shares, compared to its average volume of 2,076,640. The business’s fifty day simple moving average is $22.32 and its 200-day simple moving average is $17.93. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69. Definium Therapeutics has a fifty-two week low of $6.34 and a fifty-two week high of $26.25. The company has a market capitalization of $2.47 billion, a P/E ratio of -9.94 and a beta of 2.37.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23). As a group, equities research analysts expect that Definium Therapeutics will post -2.3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on DFTX. Wolfe Research began coverage on shares of Definium Therapeutics in a research note on Monday, February 23rd. They issued an “outperform” rating and a $25.00 target price on the stock. Leerink Partners lifted their price target on shares of Definium Therapeutics from $23.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Stifel Nicolaus set a $30.00 price target on shares of Definium Therapeutics and gave the company a “buy” rating in a research report on Thursday, April 16th. Oppenheimer reaffirmed an “outperform” rating and set a $40.00 price objective on shares of Definium Therapeutics in a research note on Thursday, April 23rd. Finally, Canaccord Genuity Group set a $38.00 price objective on shares of Definium Therapeutics and gave the stock a “buy” rating in a report on Thursday, April 16th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Definium Therapeutics has an average rating of “Buy” and a consensus target price of $37.92.

Institutional Investors Weigh In On Definium Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. CenterBook Partners LP acquired a new position in shares of Definium Therapeutics during the third quarter valued at $1,880,000. Boxer Capital Management LLC acquired a new stake in Definium Therapeutics in the third quarter worth about $1,928,000. Royce & Associates LP acquired a new stake in Definium Therapeutics in the third quarter worth about $955,000. Rosalind Advisors Inc. raised its holdings in Definium Therapeutics by 78.6% during the 3rd quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock worth $8,842,000 after purchasing an additional 330,000 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in Definium Therapeutics during the 3rd quarter valued at about $654,000. 27.91% of the stock is owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.